Sugi Predict

Sugi Predict / Compounds / SCHEMBL802765

SCHEMBL802765

SCHEMBL802765

Cc1ccc(-c2ccc(C3CCC(C)CC3)cc2)c(F)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 2/20 0.46
▸ CYP3A4 P08684 4/20 0.35
▸ CYP2C9 P11712 3/20 0.35
▸ APP P05067 2/20 0.35
▸ FASN P49327 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ TMEM97 Q5BJF2 1/20 0.32
▸ DGAT1 O75907 2/20 0.32
▸ S1PR1 P21453 2/20 0.32
▸ S1PR5 Q9H228 1/20 0.32
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SOAT1 P35610 1/20 0.31
▸ CSNK1A1 P48729 1/20 0.31
▸ CSNK1D P48730 1/20 0.31
▸ RPS6KA3 P51812 1/20 0.31
▸ ESR1 P03372 1/20 0.30
▸ TNKS O95271 1/20 0.30
▸ PARP1 P09874 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12658807 0.98 ESR2 (0.45) ESR2CYP3A4CYP2C9APPFASN
SCHEMBL15445840 0.98 ESR2 (0.45) ESR2CYP3A4CYP2C9APPFASN
SCHEMBL26167206 0.94 CYP3A4 (0.38) ESR2CYP3A4CYP2C9APPCYP2D6
SCHEMBL4549771 0.92 CYP3A4 (0.41) ESR2CYP3A4CYP2C9APPFASN
SCHEMBL4549765 0.89 ESR2 (0.47) ESR2CYP3A4CYP2C9APPFASN
SCHEMBL26672922 0.89 CYP3A4 (0.36) ESR2CYP3A4CYP2C9APPCYP2D6
SCHEMBL803146 0.88 ESR2 (0.41) ESR2CYP3A4CYP2C9APPFASN
SCHEMBL16768999 0.87 CYP3A4 (0.45) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL16769002 0.87 CYP3A4 (0.42) ESR2CYP3A4CYP2C9APPCYP2D6
SCHEMBL803232 0.87 ESR2 (0.42) ESR2CYP3A4CYP2C9APPFASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 — — US disclosed
US-20240228879-A1 LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE THEREOF JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) 2024-07-11 — — US disclosed
US-12024665-B2 Polymer-stabilized liquid crystal composition and use thereof BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) 2024-07-02 — — US disclosed
WO-2024133363-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 — — WO disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 — — US disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 — — US disclosed
US-20240026223-A1 LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) 2024-01-25 — — US disclosed
WO-2024017812-A1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-01-25 — — WO disclosed
EP-4306615-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-01-17 — — EP disclosed
US-11873438-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-01-16 — — US disclosed
US-20080071097-A1 Difluorosubstituted Heterocyclic Compounds and the Use Thereof in the Form of Components in Liquid Crystalline Media MERCK PATENT GMBH (DE) 2008-03-20 — — US disclosed
US-20080058537-A1 CYCLOPENTA[B]NAPHTHALENE DERIVATIVES LIETZAU LARS 2008-03-06 — — US disclosed
US-20080058537-A1 CYCLOPENTA[B]NAPHTHALENE DERIVATIVES LIETZAU LARS 2008-03-06 — — US disclosed
US-7326447-B2 Benzochromene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-02-05 — — US disclosed
WO-2008009417-A1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2008-01-24 — — WO disclosed
US-20080020148-A1 Chromane Derivatives Method for Production and the Use Thereof MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-01-24 — — US disclosed
US-7303791-B2 Liquid crystals having a terminal polar radical and a terminal CH3 group and simultaneously having very high specific resistances and low threshold voltages requiring a high clearing point and low rotational viscosity; matrices MERCK PATENT GMBH (DE) 2007-12-04 — — US disclosed
US-7291366-B2 Cyclopenta[b]naphthalene derivatives MERCK PATENT GMBH (DE) 2007-11-06 — — US disclosed
US-20070247585-A1 Hexahydrodibenzofuran derivatives MERCK PATENT GMBH 2007-10-25 — — US disclosed
US-20070219380-A1 Dibenzofuran Derivatives, Dibenzothiophene Derivatives and Fluorene Derivatives MERCK PATENT GMBH (DE) 2007-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080071097-A1 Difluorosubstituted Heterocyclic Compounds and the Use Thereof in the Form of Components in Liquid Crystalline Media C1S, CCND3, CCND2 ESR2 855/4885CYP3A4 441/4885CYP2C9 1460/4885
US-20070219380-A1 Dibenzofuran Derivatives, Dibenzothiophene Derivatives and Fluorene Derivatives ZYX, F3, YBX1 ESR2 1254/4885CYP3A4 1233/4885CYP2C9 2053/4885
US-20080058537-A1 CYCLOPENTA[B]NAPHTHALENE DERIVATIVES NUCB2, NDC1, JUP ESR2 3608/4885CYP3A4 1959/4885CYP2C9 3581/4885
US-20070247585-A1 Hexahydrodibenzofuran derivatives HEXD, CFD, EDF1 ESR2 2595/4885CYP3A4 392/4885CYP2C9 732/4885
US-20080020148-A1 Chromane Derivatives Method for Production and the Use Thereof C1S, CHRM1, C1R ESR2 1016/4885CYP3A4 256/4885CYP2C9 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.